The Goldman Sachs Group Boosts Ascendis Pharma A/S (NASDAQ:ASND) Price Target to $200.00
Ascendis Pharma A/S (NASDAQ:ASND – Free Report) had its price objective raised by The Goldman Sachs Group from $180.00 to $200.00 in a research note issued to investors on Tuesday morning, Benzinga reports. The brokerage currently has a buy rating on the biotechnology company’s stock. A number of other research analysts have also issued reports […]
More Stories
Theravance Biopharma (NASDAQ:TBPH) Receives “Buy” Rating from HC Wainwright
HC Wainwright reiterated their buy rating on shares of Theravance Biopharma (NASDAQ:TBPH – Free Report) in a research report report...
Tyson Foods, Inc. (NYSE:TSN) Receives $61.44 Consensus Price Target from Analysts
Tyson Foods, Inc. (NYSE:TSN – Get Free Report) has earned a consensus rating of “Hold” from the nine research firms...
Stifel Nicolaus Boosts Inseego (NASDAQ:INSG) Price Target to $17.00
Inseego (NASDAQ:INSG – Free Report) had its price objective increased by Stifel Nicolaus from $11.00 to $17.00 in a research...
Independent Bank (NASDAQ:INDB) Stock Rating Lowered by StockNews.com
StockNews.com downgraded shares of Independent Bank (NASDAQ:INDB – Free Report) from a hold rating to a sell rating in a...
Short Interest in Funko, Inc. (NASDAQ:FNKO) Decreases By 5.1%
Funko, Inc. (NASDAQ:FNKO – Get Free Report) was the target of a large decline in short interest during the month...
LCNB (NASDAQ:LCNB) Stock Rating Upgraded by StockNews.com
LCNB (NASDAQ:LCNB – Get Free Report) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating...